Haleon plc (HLN) presents an intriguing opportunity for investors seeking exposure in the healthcare sector, particularly in the specialty and generic drug manufacturing industry. With a market capitalization of $48.9 billion, this UK-based company offers a comprehensive portfolio of consumer healthcare products, spanning oral health, vitamins, pain relief, and more. Notably, Haleon’s current stock price of $10.98 is hovering near the upper end of its 52-week range of $8.72 to $11.41, suggesting a steady performance over the past year.

One of the standout aspects of Haleon’s stock is the analyst consensus, which reveals a potential upside of 7.67% from its current price, based on an average target price of $11.82. With three…